Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) and GRAIL (NASDAQ:GRAL – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.
Analyst Recommendations
This is a summary of current ratings and target prices for Kalaris Therapeutics and GRAIL, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kalaris Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
| GRAIL | 1 | 5 | 4 | 0 | 2.30 |
Kalaris Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 380.77%. GRAIL has a consensus target price of $67.78, suggesting a potential downside of 15.64%. Given Kalaris Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than GRAIL.
Insider & Institutional Ownership
Risk and Volatility
Kalaris Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, GRAIL has a beta of 3.25, meaning that its share price is 225% more volatile than the S&P 500.
Earnings & Valuation
This table compares Kalaris Therapeutics and GRAIL”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kalaris Therapeutics | N/A | N/A | -$43.44 million | ($2.02) | -1.93 |
| GRAIL | $147.17 million | 24.39 | -$408.35 million | ($9.75) | -8.24 |
Kalaris Therapeutics has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Kalaris Therapeutics and GRAIL’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kalaris Therapeutics | N/A | -71.71% | -42.95% |
| GRAIL | -236.95% | -15.88% | -14.02% |
Summary
Kalaris Therapeutics beats GRAIL on 9 of the 13 factors compared between the two stocks.
About Kalaris Therapeutics
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
About GRAIL
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
